P
Pierluigi Paggiaro
Researcher at University of Pisa
Publications - 342
Citations - 11270
Pierluigi Paggiaro is an academic researcher from University of Pisa. The author has contributed to research in topics: Asthma & Sputum. The author has an hindex of 46, co-authored 334 publications receiving 9415 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert,Claus Bachert,Joseph K. Han,Martin Desrosiers,Peter Hellings,Nikhil Amin,Stella E. Lee,Joaquim Mullol,Leon S. Greos,John V. Bosso,Tanya M. Laidlaw,Anders Cervin,Jorge Maspero,Claire Hopkins,Heidi Olze,G. Walter Canonica,Pierluigi Paggiaro,Seong H. Cho,Wytske Fokkens,Shigeharu Fujieda,M. Zhang,Xin Lu,Chunpeng Fan,Steven Draikiwicz,Siddhesh Kamat,Asif Khan,Gianluca Pirozzi,Naimish Patel,Neil M.H. Graham,Marcella Ruddy,Heribert Staudinger,David M. Weinreich,Neil Stahl,George D. Yancopoulos,Leda Mannent +34 more
TL;DR: Dupilumab significantly improved the coprimary endpoints in both studies and was added to standard of care in adults with severe CRSwNP despite previous treatment with systemic corticosteroids, surgery, or both.
Journal ArticleDOI
A summary of the new GINA strategy: a roadmap to asthma control.
Helen K. Reddel,Eric D. Bateman,Allan B. Becker,Louis-Philippe Boulet,Alvaro A. Cruz,Jeffrey M. Drazen,Tari Haahtela,Suzanne S. Hurd,Hiromasa Inoue,Johan C. de Jongste,Robert F. Lemanske,Mark L Levy,Paul M. O'Byrne,Pierluigi Paggiaro,Søren Pedersen,Emilio Pizzichini,Manuel Soto-Quiroz,Stanley J. Szefler,Gary W.K. Wong,J. Mark FitzGerald +19 more
TL;DR: The changes include a revised asthma definition, tools for assessing symptom control and risk factors for adverse outcomes, and updated strategies for adaptation and implementation of GINA recommendations.
Journal ArticleDOI
Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy
Huib A. M. Kerstjens,Michael Engel,Ronald Dahl,Pierluigi Paggiaro,E Beck,Mark Vandewalker,Ralf Sigmund,Wolfgang Seibold,Petra Moroni-Zentgraf,Eric D. Bateman +9 more
TL;DR: In patients with poorly controlled asthma despite the use of inhaled glucocorticoids and LABAs, the addition of tiotropium significantly increased the time to the first severe exacerbation and provided modest sustained bronchodilation.
Journal ArticleDOI
Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
TL;DR: Fluticasone propionate was tolerated as well as placebo, with few adverse effects and without a clinically important effect on mean serum cortisol concentration.
Journal ArticleDOI
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Nicola A. Hanania,Phillip E. Korenblat,Kenneth R. Chapman,Kenneth R. Chapman,Eric D. Bateman,Petr Kopecky,Pierluigi Paggiaro,Akihito Yokoyama,Julie Olsson,Sarah Gray,Cecile T.J. Holweg,Mark D. Eisner,Charles Asare,Saloumeh K Fischer,Kun Peng,Wendy S. Putnam,John G. Matthews +16 more
TL;DR: Lebrikizumab did not consistently show significant reduction in asthma exacerbations in biomarker-high patients, however, it blocked interleukin-13 as evidenced by the effect on interleuko-13-related pharmacodynamic biomarkers and clinically relevant changes could not be ruled out.